

**LEGISLATIVE SERVICES AGENCY  
OFFICE OF FISCAL AND MANAGEMENT ANALYSIS**

301 State House  
(317) 232-9855

**FISCAL IMPACT STATEMENT**

**LS 7179**

**BILL NUMBER:** HB 1703

**NOTE PREPARED:** Jan 13, 2003

**BILL AMENDED:**

**SUBJECT:** Medicaid preferred drug list.

**FIRST AUTHOR:** Rep. Brown C

**FIRST SPONSOR:**

**BILL STATUS:** As Introduced

**FUNDS AFFECTED:**

**GENERAL  
DEDICATED  
FEDERAL**

**IMPACT:** Pending

**Summary of Legislation:** This bill allows the Office of Medicaid Policy and Planning to add a drug that has been approved by the federal Food and Drug Administration to the preferred drug list without prior approval from the Drug Utilization Review Board (Board). Permits the Board to add a drug that has been approved by the federal Food and Drug Administration to the preferred drug list. (Current law allows: (1) the Office to add only new single source drugs to the preferred drug list without prior approval of the board; and (2) the Board to add only new single source drugs to the preferred drug list.) Makes cross references.

**Effective Date:** July 1, 2003.

**Explanation of State Expenditures:** *As of the above date, the fiscal analysis of this bill has not been completed. Please contact the Office of Fiscal and Management Analysis for an update of this fiscal impact statement.*

**Explanation of State Revenues:**

**Explanation of Local Expenditures:**

**Explanation of Local Revenues:**

**State Agencies Affected:**

**Local Agencies Affected:**

**Information Sources:**

**Fiscal Analyst:** Kathy Norris, 317-234-1360